Proprietary ClinQuick(R) system builds on a 15-year track record of
technical leadership in early clinical research
KING OF PRUSSIA, PA, July 7 /CNW/ - MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions, has launched
the next generation of its proprietary ClinQuick(R) electronic system for
Phase I study set-up, data capture, project tracking and personnel credential
management. Aimed at improving client service, the new version of the
ClinQuick(R) system extends a 15-year legacy of technical leadership in early
clinical research. System enhancements include a more user-friendly interface,
improved menu navigation and a more robust data platform. This new platform
will enable faster and more flexible reporting and will ultimately allow
clients to access their data via the internet.
"Since its implementation in 1993, ClinQuick(R) has been used
successfully in more than 3,000 Phase I studies involving nearly
100,000 participants," said MDS Pharma Services President David Spaight. "Our
investment to enhance the ClinQuick(R) system builds on that legacy of success
and will allow us to meet growing client demand for early clinical research
services while maintaining our leadership position in Phase I. This
next-generation ClinQuick(R) system will further improve our ability to
deliver high quality Phase I services on time."
Designed and built by MDS Pharma Services for use in its Phase I clinical
research centers, the fully integrated ClinQuick(R) system facilitates rapid
data cleansing and client monitoring for seamless operation of both single and
multi-site studies. ClinQuick(R) accelerates timelines, enables accurate
direct data acquisition, and reduces costs by a third compared to traditional
paper case report forms (CRFs) - the forms used by clients to collect and
document data from each participating clinical research site. The system is
fully CFR Part 11 compliant and can be used for study management and
electronic data capture (EDC), either alone or in conjunction with a
client-provided EDC system or paper CRFs. MDS Pharma Services offers one of
the world's largest capacities for conducting early-phase clinical studies,
with some 1,100 beds in five state-of-the-art clinical research facilities in
North America and Europe.
About MDS Pharma Services
MDS Pharma Services is committed to delivering quality service on time.
We offer a full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology industries. With
numerous facilities strategically located around the world, we apply advanced
scientific and technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research, early clinical
research (bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized cardiac
services. For more information, visit our website at www.mdsps.com.
MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ),
a global life sciences company that provides market-leading products and
services that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging, radiotherapeutics,
and analytical instruments. MDS has more than 5,500 highly skilled people in
29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222,
24 hours a day.
For further information:
For further information: For Investors, Kim Lee, (416) 675-6777 ext.
34721, email@example.com; For Media, Charlene McGrady, (610) 239-7900 ext.